Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate

Next Previous
Trial Profile

Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms Double-ITK-GVHc

Most Recent Events

  • 09 Jan 2023 Primary endpoint (Response rate at 3 months (complete and partial remission) after salvage treatment with Nilotinib in patients with chronic GVHD who failed Imatinib Mesylate has not been met according to Results published in the Bone Marrow Transplantation.
  • 09 Jan 2023 Results assessing Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease published in the Bone Marrow Transplantation
  • 09 Jul 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top